News
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program,
Foxconn Technology (OTCPK:FXCOF) is among potential bidders for UTAC Holdings in a transaction that could value the Singapore-based semiconductor assembly and testing company at about $3 billion.
while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback